{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:45:10Z","timestamp":1792320310195,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14696-7","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T20:11:01Z","timestamp":1754683861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database"],"prefix":"10.1186","volume":"25","author":[{"given":"Wei Fan","family":"Sui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Xin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze Feng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Mao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Hua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"issue":"3","key":"14696_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"14696_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"14696_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"17","key":"14696_CR4","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint Blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974\u201382.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14696_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58\u201367.","journal-title":"Blood"},{"issue":"8","key":"14696_CR6","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.","journal-title":"NEJM Evid"},{"key":"14696_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.033","author":"L Rimassa","year":"2025","unstructured":"Rimassa L, Chan SL, Sangro B, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.033.","journal-title":"J Hepatol"},{"key":"14696_CR8","unstructured":"AstraZeneca Pharmaceuticals LP. Imjudo-tremelimumab injection, solution: US prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process=761289. Accessed 5 Dec 2023."},{"key":"14696_CR9","unstructured":"AstraZeneca. Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers. 2022. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/imfinziimjudo-approved-in-japan-for-3-cancers.html\/. Accessed 5 Dec 2023."},{"key":"14696_CR10","unstructured":"AstraZeneca AB. Imjudo: summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imjudo#product-information-section. Accessed 5 Dec 2023."},{"issue":"1","key":"14696_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40360-024-00821-y","volume":"25","author":"T Zou","year":"2024","unstructured":"Zou T, Li Z, Wang T, et al. A real-world disproportionality analysis of the US food and drug administration (FDA) adverse event reporting system (FAERS) events for durvalumab. BMC Pharmacol Toxicol. 2024;25(1):97\u2013104.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"14696_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11096-023-01678-7","volume":"46","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Jiang H, Xue L, et al. Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system. Int J Clin Pharm. 2024;46(2):480\u20137.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"14696_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"14696_CR14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1186\/s12889-025-22026-6","volume":"25","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Zeng G, Dai H, Bian Y, Wang L, Cao W, Yang J. Global, regional and National burden of liver cancer 1990\u20132021: a systematic analysis of the global burden of disease study 2021. BMC Public Health. 2025;25(1):931\u201352.","journal-title":"BMC Public Health"},{"issue":"3","key":"14696_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.5415\/apallergy.0000000000000146","volume":"14","author":"H Sutanto","year":"2024","unstructured":"Sutanto H, Safira A, Fetarayani D. From tumor to tolerance: a comprehensive review of immune checkpoint inhibitors and immune-related adverse events. Asia Pac Allergy. 2024;14(3):124\u201338.","journal-title":"Asia Pac Allergy"},{"issue":"6","key":"14696_CR16","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.cgh.2020.01.033","volume":"18","author":"M Collins","year":"2020","unstructured":"Collins M, Soularue E, Marthey L, et al. Management of patients with immune checkpoint Inhibitor-Induced enterocolitis: a systematic review. Clin Gastroenterol Hepatol. 2020;18(6):1393\u2013403.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"27","key":"14696_CR17","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","volume":"39","author":"RK Kelley","year":"2021","unstructured":"Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of Tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study. J Clin Oncol. 2021;39(27):2991\u20133001.","journal-title":"J Clin Oncol"},{"issue":"3","key":"14696_CR18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","volume":"31","author":"LT Chen","year":"2020","unstructured":"Chen LT, Martinelli E, Cheng AL, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31(3):334\u201351.","journal-title":"Ann Oncol"},{"issue":"3","key":"14696_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345\u201361.","journal-title":"Am J Clin Dermatol"},{"issue":"18","key":"14696_CR20","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint Blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"issue":"7","key":"14696_CR21","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/ijc.34813","volume":"154","author":"C Niu","year":"2024","unstructured":"Niu C, Zhu K, Zhang J, et al. Analysis of immune-related adverse events in gastrointestinal malignancy patients treated with immune checkpoint inhibitors. Int J Cancer. 2024;154(7):1261\u201371.","journal-title":"Int J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14696-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14696-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14696-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T20:03:52Z","timestamp":1757361832000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14696-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14696"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14696-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1289"}}